Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | TFEB | P19484 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129242 | 0.84 | HTT (0.55) | HTTGAASMN1; SMN2PTGER1PTGER4 | |
| SCHEMBL3129248 | 0.84 | HTT (0.55) | HTTGAASMN1; SMN2PTGER1PTGER4 | |
| Coumarinic Acid Methyl Ether SCHEMBL29369917 | 0.81 | NFE2L2 (0.77) | HTTGAASMN1; SMN2NFE2L2TFEB | |
| Coumarinic Acid Methyl Ether SCHEMBL714857 | 0.81 | NFE2L2 (0.77) | HTTGAASMN1; SMN2NFE2L2TFEB | |
| Coumarinic Acid Methyl Ether SCHEMBL83064 | 0.81 | NFE2L2 (0.77) | HTTGAASMN1; SMN2NFE2L2TFEB | |
| Coumarinic Acid Methyl Ether SCHEMBL79060 | 0.81 | NFE2L2 (0.77) | HTTGAASMN1; SMN2NFE2L2TFEB | |
| SCHEMBL28736836 | 0.80 | MAPT (0.48) | HTTGAASMN1; SMN2MAPTKDM4E | |
| Coumarinic Acid Methyl Ether SCHEMBL8351832 | 0.79 | NFE2L2 (0.74) | HTTGAASMN1; SMN2NFE2L2TFEB | |
| Coumarinic Acid Methyl Ether SCHEMBL10437229 | 0.79 | NFE2L2 (0.74) | HTTGAASMN1; SMN2NFE2L2TFEB | |
| Coumarinic Acid Methyl Ether SCHEMBL4743620 | 0.79 | NFE2L2 (0.74) | HTTGAASMN1; SMN2NFE2L2TFEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213472-B2 | VEGFC production promoter | SHISEIDO COMPANY, LTD. (JP) | 2022-01-04 | — | — | US | disclosed |
| US-11160747-B2 | Unevenness correction cosmetic | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-11-02 | — | — | US | disclosed |
| EP-2902022-B1 | VEGFC PRODUCTION PROMOTER | SHISEIDO CO LTD (JP) | 2020-10-28 | — | — | EP | disclosed |
| US-20200222294-A1 | VEGFC PRODUCTION PROMOTER | SHISEIDO COMPANY, LTD. (JP) | 2020-07-16 | — | — | US | disclosed |
| US-10624829-B2 | VEGFC production promoter | SHISEIDO COMPANY, LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20190350835-A1 | UNEVENNESS CORRECTION COSMETIC | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
| US-10470989-B2 | Surface-treated powder using theanine, and cosmetic preparation containing same | KOSE CORPORATION (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20170281500-A1 | VEGFC PRODUCTION PROMOTER | SHISEIDO COMPANY, LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20160271032-A1 | SURFACE-TREATED POWDER USING THEANINE, AND COSMETIC PREPARATION CONTAINING SAME | KOSE CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20150328137-A1 | VEGFC PRODUCTION PROMOTER | SHISEIDO COMPANY, LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2902022-A1 | VEGFC PRODUCTION PROMOTER | Shiseido Company Ltd. (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8252273-B2 | Ultraviolet absorber | LEAD CHEMICAL CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2192106-B1 | ULTRAVIOLET ABSORBER | LEAD CHEM CO LTD (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20100239508-A1 | ULTRAVIOLET ABSORBER | LEAD CHEMICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2192106-A1 | ULTRAVIOLET ABSORBER | Lead Chemical Co. Ltd. (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-20050129618-A1 | Drugs for ameliorating itch, rough skin or hypersensitive skin or for whitening via inhibition of the production and release of stem cell factor | SHISEIDO CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1457780-A1 | DRUGS FOR AMELIORATING ITCH, ROUGH SKIN OR HYPERSENSITIVE SKIN OR FOR WHITENING VIA INHIBITION OF THE PRODUCTION AND RELEASE OF STEM CELL FACTOR | SHISEIDO COMPANY LIMITED (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239508-A1 | ULTRAVIOLET ABSORBER | UNG, UACA, ABCG2 | HTT 1302/4885GAA 712/4885SMN1; SMN2 4286/4885 |
| US-20150328137-A1 | VEGFC PRODUCTION PROMOTER | VEGFA, LRBA, NOS3 | HTT 4509/4885GAA 3907/4885SMN1; SMN2 4465/4885 |
| US-10624829-B2 | VEGFC production promoter | VEGFA, LRBA, NOS3 | HTT 4509/4885GAA 3907/4885SMN1; SMN2 4465/4885 |
| US-20170281500-A1 | VEGFC PRODUCTION PROMOTER | VEGFA, LRBA, NOS3 | HTT 4509/4885GAA 3907/4885SMN1; SMN2 4465/4885 |
| US-11213472-B2 | VEGFC production promoter | VEGFA, LRBA, NOS3 | HTT 4509/4885GAA 3907/4885SMN1; SMN2 4465/4885 |
| US-20200222294-A1 | VEGFC PRODUCTION PROMOTER | VEGFA, LRBA, NOS3 | HTT 4509/4885GAA 3907/4885SMN1; SMN2 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.